Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

P&G to Help Syneron Smooth Its Customers

By Matt Koppenheffer - Updated Nov 15, 2016 at 1:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The consumer-goods giant teams up with the small cap to treat consumers' skin.

First and foremost, I have to give that rule-breaking Jim Cramer a big thanks. Not two weeks after I called out Syneron (NASDAQ:ELOS) as the best small cap for 2007, big Jim gave Syneron the ol' "booyah," which sent the stock popping 8.6%.

While Cramer focused on the company's new dental lasers, another area that had been simmering in the oven sent the stock soaring again today. Syneron's current revenues come from sales of the company's various energy-based beautification systems into professional environments, such as doctors' offices. Today, Syneron announced a 10-year exclusive agreement with consumer-goods giant Procter & Gamble (NYSE:PG) to market its planned home-use product.

As far as the market potential, I'll echo what the company said on today's conference call: There's probably no need to convince anyone of how big the market is for a home-use product that makes people look younger and their skin look better.

Syneron will be responsible for development and manufacturing of the product, while P&G's $21 billion beauty business will be the marketing force behind it. Syneron is also hoping for some halo effect from the new consumer devices to increase awareness for Syneron products in professional settings.

The real question for investors, though, is how these new products will impact the company's financials. The most obvious effect will be on the top line -- these new products will give Syneron exposure to a much larger market and should drive significant revenue growth. The company will also be unloading a lot of the operational expenses, such as sales and marketing, associated with the new products. Operational costs have been weighing on Syneron's bottom line as it competes heavily in the professional market with competitors like Cutera (NASDAQ:CUTR) and Palomar (NASDAQ:PMTI) (which has been working with P&G subsidiary Gillette on home-use hair-removal products since 2003).

On the flipside, the home-use products are expected to sell for less than $1,000 and should have a far lower gross margin than the 85% that Syneron enjoys on its current products. Details on the economics of the link-up were slim, but in an outstanding comment, the company's chairman quipped that there will be "lots of room for everybody to make lots of money" while still putting out a reasonably priced product.

I continue to be wary of the outsized growth of Syneron's operational expenses, but the numbers it released for the 2006 fiscal year show strong top-line growth and very satisfying gross margins. This new agreement should be a big positive for the company in helping it to diversify its business and continue to strengthen its brand.

Shed some more light on light-based beauty:

Crazy for small caps? So is the team at Motley Fool Hidden Gems! You can try the newsletter free for 30 days.

Fool contributor Matt Koppenheffer hopes that Syneron's home-use products are still around when it's time for him to iron out wrinkles. He owns shares of Syneron, but does not own any of the other companies mentioned. The Fool's disclosure policy keeps you looking young and fresh.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Procter & Gamble Company Stock Quote
The Procter & Gamble Company
PG
$151.63 (-0.34%) $0.52
Syneron Medical Ltd. Stock Quote
Syneron Medical Ltd.
ELOS
Cutera Stock Quote
Cutera
CUTR
$39.58 (9.79%) $3.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.